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Methotrexate has historically thought to be able to cause pulmonary fibrosis and this 
potential side effect is listed in major textbooks, patient information leaflets and 
national guidelines.1 This belief is based on a very small number of previously 
published isolated case reports; however, when these reports are scrutinised, such 
cases of pulmonary fibrosis arising many years after the introduction of methotrexate 
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could represent other interstitial lung diseases unrelated to methotrexate.2,3 Once 
dogma is established, it can be difficult to undo. 
An 83-year-old man was admitted with dyspnoea and a productive cough. Chest x-
ray and high resolution CT demonstrated extensive pulmonary fibrosis with 
superimposed pneumonia. Medical history included previous cigarette smoking and 
methotrexate therapy for 10 years for psoriasis (average weekly dose of 5mg) which 
was stopped. He improved with initial treatment but had residual persistent 
significant respiratory failure and pulmonary hypertension requiring long-term home 
oxygen. He died 10 months later. The cause of death was considered to be 
idiopathic pulmonary fibrosis – the commonest form of interstitial lung disease but his 
family were concerned that the methotrexate he had been taking was to blame.. 
Interstitial lung disease (ILD) encompasses a large and heterogeneous group of 
parenchymal lung disorders, which overlap in their clinical presentations and 
patterns of lung injury.4 Types of progressive ILD include autoimmune eg. associated 
with rheumatoid arthritis, Sjogren’s syndrome, systemic sclerosis or 
dermatomyositis; pulmonary sarcoidosis,  and exposure-related eg. inhalation of 
asbestos or silica.4 Pathogenetic mechanisms are complex and research is ongoing 
to attempt to clarify areas of uncertainty including identifying markers / predictors of 
disease progression, selection of patients for treatment and the role of 
immunosuppressive therapy and antifibrotic therapy.4 
In recent years, higher quality evidence has demonstrated a lack of association 
between methotrexate and pulmonary fibrosis.5,6 However, acute pulmonary toxicity 
in the form of interstitial pneumonitis is a recognised very rare side-effect which is 
idiosyncratic and almost always presents within the first 12 months of methotrexate 
therapy with dyspnoea, cough and fever with systemic upset. On cessation of 
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methotrexate and appropriate acute treatment, the clinical features usually resolve 
and there are no long term sequelae. However, there are isolated reports of 
methotrexate-associated pneumonitis not responding to drug cessation and active 
treatment and so it is important that patients stop methotrexate and seek a medical 
assessment if they develop respiratory symptoms. 
 We wish to raise awareness of the possibility of coexisting pulmonary fibrosis with 
psoriasis and methotrexate therapy and to emphasise the lack of causation. We 
recommend that guidelines and information leaflets are updated to reflect expert 
respiratory medicine opinion and the latest evidence to avoid confusion and distress 
to patients and their families and prescribers of methotrexate. Interestingly, package 
leaflets for methotrexate and the main UK rheumatology charity organisation “Versus 
Arthritis” do not mention pulmonary fibrosis as a side effect but rather “fluid on the 
lungs” and “inflammation of the lungs” which is an accurate description of 
pneumonitis. It is very important to differentiate pneumonitis from fibrosis as 
prognosis is different. One must also not falsely implicate blame on a medication. 
We advocate removing pulmonary fibrosis as a listed side-effect of low-dose weekly 
methotrexate therapy. Acute lung toxicity in the form of pneumonitis should continue 
to be stated as a rare side-effect. 
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